Diploma (OTCPK:DPLM.F) Trading update Transcript

Summary of Diploma Trading Update Conference Call Company Overview - Company: Diploma (OTCPK:DPLM.F) - Date of Call: March 18, 2026 Key Points Industry and Company Performance - Organic Growth Guidance: Increased from 6% to 9% for the year, indicating strong performance in the first half and confidence in the second half [2][5] - Margins: Operating margins improved from 22.5% to 25%, contributing to a 13% increase in consensus operating profit [2] - Peerless Performance: Continues to perform well, with sustainable market dynamics and share gains [2][3] Segment Performance - Controls Segment: - IS Group and Clarendon are performing exceptionally well, with double-digit growth and margin improvements, particularly in energy, defense, and aerospace markets [3][12] - Windy City Wire is benefiting from data centers and distributed antenna systems [3] - International Markets: - RNG in the UK is facing challenges, impacting sector growth [4] - Life Sciences: Stable growth at mid-single digits, with market share gains expected despite tough conditions in healthcare [4][26] Market Dynamics - Demand Environment: Remains strong with a significant backlog of new builds and refurbishment opportunities [16] - Supply Chain: Constraints are expected to persist for the next 1-3 years, but the company is well-positioned to manage potential pricing inflation due to energy costs [10][16] Acquisitions and Growth Strategy - Acquisitions: Eight acquisitions totaling GBP 130 million have been made, with a healthy short-term pipeline for further opportunities [4][31] - M&A Outlook: Optimism for small bilateral deals, with a focus on enhancing growth potential in key markets [31][32] Future Expectations - Earnings Growth: Expected to increase by over 20% this year, with strong returns on capital [5] - Sustainability of Margins: While current margins are at the top end, future acquisitions may dilute margins, but absolute profit is expected to continue growing [42][43] Additional Insights - Defense Market: Represents a small percentage of revenue but is seen as a significant growth opportunity, with investments in new facilities and expertise [24][25] - Market Share in Life Sciences: Expected growth in MedTech and IVD markets, with a target of 4%-6% growth for the half year [26][27] Conclusion - The company is in a strong position with positive growth prospects across various segments, supported by strategic acquisitions and a diversified market presence. The focus on sustainable quality compounding and effective management of supply chain challenges will be crucial for future performance [47]